Skip to Content
Merck
  • Ceftriaxone-induced hemolytic anemia: case report and review of literature.

Ceftriaxone-induced hemolytic anemia: case report and review of literature.

Journal of pediatric hematology/oncology (2014-06-01)
Michael S Northrop, Hemant S Agarwal
ABSTRACT

Ceftriaxone is a frequently used empiric antibiotic in children. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with a high mortality rate. A 14-year-old boy suffering from Crohn disease developed bacterial pneumonia that was treated with ceftriaxone. We report successful management of ceftriaxone-induced hemolytic anemia (CIHA) in this patient and review the CIHA literature in pediatric patients. Early recognition of CIHA with prompt discontinuation of ceftriaxone therapy may have a beneficial role in reduction of high mortality seen in these patients.

MATERIALS
Product Number
Brand
Product Description

Ceftriaxone sodium, European Pharmacopoeia (EP) Reference Standard
USP
Ceftriaxone sodium, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ceftriaxone disodium salt hemi(heptahydrate), third-generation cephalosporin antibiotic
Supelco
Ceftriaxone Sodium, Pharmaceutical Secondary Standard; Certified Reference Material